Proteolysis targeting chimeras (PROTACs) in cancer therapy

Alberto Ocaña1,2,3* and Atanasio Pandiella2,4

Abstract

Exploitation of the protein degradation machinery as a therapeutic strategy to degrade oncogenic proteins is experiencing revolutionary advances with the development of proteolysis targeting chimeras (PROTACs). PROTACs are heterobifunctional structures consisting of a ligand that binds a protein to be degraded and a ligand for an E3 ubiquitin ligase. The bridging between the protein of interest and the E3 ligase mediated by the PROTAC facilitates ubiquitination of the protein and its proteasomal degradation. In this review we discuss the molecular medicine behind PROTAC mechanism of action, with special emphasis on recent developments and their potential translation to the clinical setting.

Keywords: PROTACs, BET inhibitors, Proteasome, Ubiquitination, Protein degradation

Novel druggable vulnerabilities in cancer

Cancer is a multistep process in which genomic and epigenomic alterations lead to the abnormal cellular proliferation and dissemination [1]. Identification of molecular vulnerabilities that maintain the oncogenic phenotype has attracted major interest as the first step for the development of novel therapeutics [2].

A disbalance in the homeostasis of the protein production can be an oncogenic vulnerability in some tumors [3, 4], as demonstrated by the arrival of proteasome inhibitors to the oncology clinic [3, 4]. A novel class of agents that exploit the cellular protein degradation machinery with therapeutic purposes are the Proteolysis Targeting Chimeras or PROTACs [5]. These compounds can be used to facilitate proteasomal degradation of proteins that participate in the prooncogenic process. Importantly, PROTACs can be used to target a variety of proteins, including those with enzymatic activity or others difficult to target, such as those with scaffolding properties [3]. That is the case of transcription factors (TFs) (see glossary), which represent a large family of proteins against which very limited therapeutic options exist [6, 7]. TFs, as well as nuclear receptors, have been involved in the oncogenic generation of several malignancies. In fact, genomic alterations in c-MYC, FOXO1 or the androgen receptor (AR) have been described in neuroblastoma, breast or prostate cancer, respectively [6, 8]. A therapeutic strategy that has been contemplated is the reduction of the expression of these proteins by inducing their degradation. In this context, two PROTACs targeting the AR and estrogen receptor (ER) have reached the clinical setting being explored in two phase I studies in prostate and estrogen receptor-positive breast cancer [9].

In this review we will focus on strategies to increase protein degradation of druggable and undruggable targets focusing on PROTACs, describing the current stage, the main limitations and their potential for improvement.

Targeting protein degradation

Cell homeostasis depends on an accurate control of the quantity and quality of constituent proteins [10, 11]. This is more necessary in cells that have a high rate of turnover as they need to synthesize and consequently...
degrade proteins in an efficient manner [10, 11]. Protein degradation may occur in the lysosomes, by the action of acidic proteases that degrade proteins reaching these organelles [12]. Such situation is observed in the case of membrane receptors, that may increase their internalization and targeting to the lysosomes upon activation by their ligands or after binding to anti-receptor antibodies. This characteristic is exploited in the case of therapeutic antibody-drug conjugates (ADCs), a sophisticated evolution of anti-receptor antibodies. ADCs are composed of three components: an antibody against a protein expressed on the surface of tumor cells, a chemotherapeutic agent, and a linker that binds both. Upon interaction with the cell surface protein, the latter is driven to the endocytic lysosomal route. In the lysosomes, the ADC is proteolytically degraded facilitating the release of membrane-permeant cytotoxic drugs outside the lysosome to reach its cellular target. Acting on the lysosome has been less explored, although some recent preclinical studies have demonstrated the potential utility of this strategy, at least for the treatment of some proteinopathies [13].

Another major proteolytic system is the ubiquitin-proteasome degradation pathway, which relies on the ubiquitination of proteins, a process that triggers their degradation [14]. The targeting of an oncogenic protein or a protein not essential for the oncogenic phenotype but critical in the proliferation process, may also result in clinical benefit. This strategy needs ubiquitination of a target protein to subsequently be recognized by the proteasome [15].

**Protein degradation and the ubiquitination system**

Proteasomal-mediated protein degradation is an ordered multistep and sequential process, which requires several enzymatic reactions [16]. Ubiquitination is produced by three different steps: (i) activation by an E1 Ub-activating enzyme, (ii) conjugation mediated by the E2-conjugating enzyme, and finally (iii) ligation that is produced by the E3-protein ligases (Fig. 1) [17, 18]. In mammalian cells there are two E1 that can bind to forty E2s, which can bind with hundreds of E3s in a hierarchical way [19]. In the activation process, E1 enzymes bind both ATP and ubiquitin and catalyse the acyladenylation of the C-terminus of the ubiquitin molecule and transfer ubiquitin to a cysteine residue producing a thioester linkage between the C-terminal carboxyl group of ubiquitin and the sulfhydryl group of the E1 cysteine [17, 18]. E1-thioesterified ubiquitin is then ready to transfer the latter to a cysteine located in the active center of an E2 conjugating enzyme [20]. Finally, in the ligation process, E3 ligases act bridging the E2-ubiquitin and the substrate and create an isopeptide bond between a lysine of the target protein and the C-terminal glycine of ubiquitin. This last step provides the substrate specificity of the reaction as there are hundreds of E3 ligases, being the majority of them included in two families: the HECT and the RING ligases [21, 22]. In addition, these ligases vary depending on cellular and tissue contexts, diversifying their protein substrates [23]. Rpn receptors present in the 19S unit of the proteasome help degradation of tagged proteins acting as binding sites [23]. Proteins entering the proteasome are then degraded by peptidases of the 20S region, resulting in the formation of fragmented proteins and the removal of ubiquitin from the protein being degraded [23].

**Development of PROTACS**

PROTACs take advantage of the ubiquitin-mediated degradation system as a therapeutic strategy. A PROTAC is a molecule that consists of three parts: (i) a ligand (warhead) that interacts with the protein to be degraded, (ii) a different ligand that binds to an E3 ubiquitin ligase and (iii) a linker that connects both ligands (Fig. 1) [5]. The proximity between the E3 ligase and the protein target achieved by the heterobifunctional PROTAC facilitates ubiquitination and degradation of the protein target. First PROTAC compounds were developed more than 20 years ago using the E3 ligase TRCP [24]. Of note in this work the phosphopeptide ligand for TRCP did not penetrate the cellular membrane, limiting their development [24]. That aspect merits consideration as membrane permeation still represents a limiting step in the development of PROTACs. Later on, peptide ligands were changed to small molecules to avoid the low potency and to increase the cell permeability [25]. Nutlin-3 a a ligand of the E3 ligase MDM2 was then used, showing capacity to degrade the androgen receptor [25].

Several structural studies have helped in the development of PROTACs. For instance, Van Molle and colleagues used a fragment based lead discovery approach to identify regions in VHL that are used for its interaction with the target protein hypoxia inducible factor1α (HIF1α) [26]. Crystal structures revealed a site of interaction of VHL with a 19 amino acid peptide derived from HIF1α. In silico and structural analyses identified three drugs that bound to the same site in VHL as the HIF1α peptide and acted as competitors of that protein-protein interaction [26, 27]. An ulterior study in the same experimental setting allowed development of drugs with better membrane permeabilization properties [28]. The above studies allowed identification of the groove on the surface of pVHL that was used to interact with a region of HIF1α, paving the way to the development of VHL-based PROTACs.
An important effort was made to develop warheads to target the nuclear hormone receptors AR and ER, generating a series of PROTACs which showed preclinical activity [29–34]. Other warheads that were developed later included known tyrosine kinase inhibitors, or novel families of epigenetic agents like the Bromo and Extraterminal Domain inhibitors (BETi) [31, 33]. These proteins belong to super enhancer complexes that regulate the expression of TFs, indirectly modulating transcription initiation and elongation [35]. Most studies evaluating BET-PROTACs have been performed in leukemia and lymphoma, followed by some indications in solid tumors like prostate cancer, triple negative breast cancer or osteosarcoma (Table 1). BETi provided a therapeutic opportunity to target transcription, especially due to the difficulties in targeting TFs, which were considered as undruggable targets [43]. BETi have shown antitumoral activity in several haematological malignancies and solid tumors [43, 44], and BET-PROTACs were developed with the aim to boost and prolong the pharmacological effect of these agents, increasing their anti-tumoral activity. Beyond the activity of BET-PROTACs in different solid and hematologic tumors, these agents have also demonstrated activity in preclinical models that were resistant to BETi, suggesting that resistant tumors still depend on these proteins [38].

Additional PROTACs targeting other components of the transcription machinery include those based on inhibitors of CDK9 or SMARCA2/4 [45–49]. PROTACs based on inhibitors targeting ALK or CDK6 kinases or
based on inhibitors of the BCL6, BCL-XL or MCL1 apoptotic machinery components have also been developed [50–55]. Supplementary Table 2 shows a complete list of PROTACs explored in preclinical studies.

Although many of these agents have been designed and evaluated preclinically, only two PROTACs, ARV-110 and ARV-471, have entered the clinical setting. ARV-110, a PROTAC designed to provoke degradation of the AR is being analysed in patients with castration resistant metastatic prostate cancer who have progressed on at least two prior therapies (enzalutamide or abiraterone, see clinicaltrials.gov reference NCT03888612). ARV-471, that provokes the degradation of the ER, is being explored in ER positive locally advanced or metastatic breast cancer (NCT04072952) [9]. Figure 2 describes all the chronological process for the development of this family of agents including information for each compound.

**Table 1** Reported studies evaluating BET-PROTACs

| Transcription factor | Ligand for E3 ligases | Cancer type | BET Inhibitor | PROTAC | Reference |
|----------------------|----------------------|-------------|---------------|--------|-----------|
| BRD4                 | Von Hippel-Lindau (VHL) E3 ligase, E3 ubiquitin ligase CRBN | Osteosarcoma, leukemia | JQ1 | BETd-260 | [36] |
| BRD4                 | E3 ubiquitin ligase CRBN | Leukemia, Burkitt’s Lymphoma | Oxazepines, JQ1, OTX | QCA570, ARV-825 | [34, 37] |
| BRD1, BRD2 and BRD4  | E3 ubiquitin ligase CRBN | Burkitt’s lymphoma | JQ1, OTX | ARV-825 | [34] |
| BRD4 over BRD2 and BRD3 | Von Hippel-Lindau (VHL) E3 ligase | Cervical carcinoma | JQ1 | MZI | [33] |
| BRD4                 | Von Hippel-Lindau (VHL) E3 ligase | Triple negative Breast Cancer and JQ1 resistant cells | JQ1 | MZI | [38] |
| BRD2, BRD3 and BRD4  | E3 ubiquitin ligase CRBN | Leukemia | JQ1 | dBT1 | [31] |
| BRD2, BRD3 and BRD4  | E3 ubiquitin ligase CRBN | Triple negative Breast Cancer | BETi-211 | BETd-246 | [39] |
| Pan BET degrader     | Von Hippel-Lindau (VHL) E3 ligase | Prostate cancer | BETInhibitor | ARV-771 | [40] |
| Bromodomain containing proteins: BRD9 | E3 ubiquitin ligase CRBN | AML | BRD9 inhibitor | dBRD9 | [41] |
| Bromodomain containing proteins: BRD7/BRD9 | Von Hippel-Lindau (VHL) E3 ligase | Leukemia | BRD9/BRD7 inhibitor | VZ185 | [42] |

**Fig. 2** Chronological representation of all different types of PROTACs since 2001 including the structure and type of ligase. Information about the type of warhead is also included particularly for the most recent compounds.
Optimizing PROTACs
There is still much room to optimize this family of relatively new agents. For instance, it is relevant to mention that only 1% of the more than 500 E3 ligases have been explored for target degradation, and the selection of the E3 pairing seems to be critical [56]. Indeed, E3 ligases dictate target specificity [56]. Only few ligases have been explored, including CRBN, VHL, IAPs, MDM2, DCAF15, DCAF16 and RNF114, but only CRBN and VHL have shown activity in preclinical models [56]. Adequate optimization of the selection of the E3 ligases may increase efficacy and decrease potential toxicity of the PROTACs. One opportunity is based in their tissue specific expression. Thus, ASB9, a SOCS box E3 ligase, is only expressed in pancreatic and testis tissue, and FBXL16 is mainly found in the cerebral cortex, providing the possibility of acting on diseases affecting those tissues [56]. Similarly, if a ligase is only expressed in specific cellular components it can be used to degrade proteins located at that particular cellular site, as is the case for the use of the nuclear E3 ligase DCAF16 for nuclear targets [57]. Another example is represented by the action of CRBN against Ikaros and Aiolos, both nuclear proteins [3, 56].

Other parameters beyond the mere presence of the E3 ligase have to be taken into consideration when evaluating how active a PROTAC can be. Thus, ideally, the interaction between the ligand for the protein of interest and the E3 ligase should promote the formation of ternary complexes (Protein of interest-PROTAC-E3 ligase), leading to polyubiquitination of the protein and subsequent proteasomal degradation. However, in some circumstances such ternary complex may fail to be produced. That may happen, for example, in case the concentration of the PROTAC is in large excess with respect to the E3 ligase and the protein target. Since PROTACs are bifunctional molecules, they may independently bind to two molecules: the E3 ligase and the protein target. Desirably, one PROTAC molecule would act as a bridge between one E3 ligase and one protein target, creating a ternary complex. In case high concentrations of the PROTAC are present, it is possible the formation of binary complexes (protein target-PROTAC, or E3 ligase -PROTAC) that are ineffective [58]. In this circumstance, the right equilibrium is not achieved, since elevated PROTAC concentrations would saturate binding sites on the E3 ligase on one side and on the protein target on the other side, exhausting free forms of these proteins that could be used for ternary complexes. This process, produced when high concentrations of the PROTAC are present, is called the “hook effect” [58, 59]. It is relevant to mention that some PROTACs such as MZ1 may mitigate the hook effect as they exhibit positive cooperativity with respect to the assembly of ternary complexes.

The chemical characteristics of the linker can also affect the degradation capacity of the PROTAC. For instance the linker length can modify the degradation profile of laptinib-based PROTACs targeting the EGFR and HER2 or only EGFR [60]. A similar finding was observed when different linkers were developed tethering JQ1 to VHL-1 showing that some PROTACs were able to degrade BRD2–4 and others were specifically selective for BRD4 [33].

Exploiting the use of PROTACs in the clinical setting

Inhibition versus degradation
In the case of certain proteins, especially those with enzymatic activity, PROTACs can have a double mechanism of action. In fact, PROTACs based on inhibitors of the kinase activity of a protein should retain the beneficial properties of inhibiting the kinase in addition to the capability of the PROTAC to reduce the amount of the protein kinase. These two effects sum to achieve an even greater inhibitory action on the protein kinase, as compared to the mere inhibition of the kinase activity. In fact, PROTACs can potentially be more effective as they induce target degradation rather than solely target inhibition and the effect can be prolonged as it depends on the resynthesis rate of the inhibited protein [3, 32, 61–65]. Some recent examples have demonstrated that low affinity warheads can induce degradation of targets of interests, being more efficient that just their chemical inhibition, as has been demonstrated for p38 [66]. In that report, the best predictor of efficacy was ternary complex formation. Indeed, of the 54 kinases inhibited by the kinase inhibitor foretinib, 14 were degraded by the CRBN-based PROTAC and 9 by the VHL PROTAC and six by both [66].

A limitation for all drug modalities that target proteins including PROTACs is how much protein is needed to be degraded to induce a biological effect. However, degraders, as a catalytic modality, are troubled less by this issue as they do not depend on receptor occupancy. Another aspect that requires refinement is the elucidation of the most adequate competent poly-ubiquitination process to mediate the effect. Lack of activity of a recent described PROTAC with an inhibitor of KRAS as a warhead was explained by the limitation of the poly-ubiquitination process due to the electrostatic interactions produced by the poly-lysines in the C-terminus of KRAS [67]. Indeed, in some cases ubiquitination of the target does not occur [64].

Reducing clinical toxicities
It is considered that PROTACs could be potentially toxic due to several reasons. The first one is that if the targeted protein is widely expressed in non-transformed tissues, its degradation can produce serious on-target
side effects when applied to patients [5]. However, several strategies could be used to reduce this problem. As described before E3 tissue specificity can be incorporated to reduce on target dose-limiting toxicities. A recent example of this has been described with the development of a BCL-XL PROTAC. BCL-XL inhibitors were not approved for the treatment of B cell lymphoma due to its on-target and dose limiting toxicity, mainly thrombocytopenia [53]. Since the VHL E3 ligase is poorly expressed in platelets, BCL-XL PROTACs targeted for degradation by that ligase do not induce thrombocytopenia, maintaining the same therapeutic efficacy as VHL is expressed in the lymphomatous cells [68]. In a similar way, presence of ligases in specific tissues can increase the activity in those places reducing the toxicities in other cells [56]. It is therefore expected that an appropriate selection of the target protein and the E3 ligase will not only increase specificity, but augment effectiveness and reduce side effects.

Another strategy to reduce toxicity is the vectorization of these compounds with antibodies so the compound can specifically reach the tumoral cell. This can be done creating a PROTAC-ADC or with the incorporation of PROTACs into nanoparticles that can secondarily be vectorised with antibodies [68–70]. A proof of concept example of this approach is the report of an ADC by attaching a BET degrader to an anti-CLL1 antibody [71].

Clinical implications: overcoming mechanisms of resistance
A classical mechanism of resistance to kinase inhibitors is the presence of primary or secondary mutations in the kinase domain that decrease or prevent the binding of the compound in the ATP pocket. For instance, mutations in Brutons tyrosine kinase are involved in resistance to ibrutinib, an inhibitor of this kinase that is approved for the treatment of several haematological malignancies such as relapse/refractory mantle cell lymphoma, chronic lymphocytic leukemia and Waldenström macroglobulinemia [72, 73]. Analogously, it is well known that mutations in the chimeric oncogene BCR/ABL cause resistance to tyrosine kinase inhibitors used in chronic myeloid leukemia [74]. In the case of solid tumors, mutations in the EGFR, such as the T790M have been associated to resistance to first generation EGFR kinase inhibitors such as gefitinib or erlotinib [74]. For these diseases in which tyrosine kinases play a pathophysiological role, development of PROTACs with a warhead able to bind the mutated kinase, for example at an allosteric site, could result in a stable interaction potentially rescuing the resistance [75].

Resistance due to mutations in proteins which lack enzymatic activity can also be bypassed by PROTACs. Thus, PROTACs targeting the ER in breast cancer could rescue resistance to anti-estrogens when this resistance is mediated by mutations at the ER, supporting the development of ER PROTACs in this situation [76]. Moreover, in prostate cancer AR PROTACs have demonstrated more efficacy than enzalutamide in castration resistance prostate cancer, opening the door to the development of AR-PROTACs in the clinic [40, 77].

Mechanisms of resistance to PROTACs
Several studies indicated that genomic alterations affecting protein integrity of components of the ubiquitin-proteasome system may be behind resistance to PROTACs. Loss of E2 or E3 ligases or the cullin (CUL) proteins have been implicated. Zhang and colleagues observed that resistance to CRBN-based BET-PROTACs was provoked by chromosomal deletion of the CRBN gene [78]. On the other hand, resistance to VHL-based BET-PROTACs was found to occur by cullin-2 (CUL2) loss of function due to several genomic alterations in the CUL2 locus, including exon 12 skipping or frame shift mutations which gave rise to a premature stop codon [78]. Similar findings were also observed by Ottis et al. [79]. Using RNAi of components of the ubiquitin-proteasome system in cells made resistant to BET-PROTACs confirmed that down-regulation or loss of those proteins may lead to PROTAC resistance [79]. Those authors also identified the COP9 signalosome as implicated in the function of BET-PROTACs. Using a CRISPR/Cas9 screen to define effectors involved in targeted protein degradation, Mayor-Ruiz and colleagues confirmed a role of the COP9 signalosome and CUL proteins in the regulation of targeted protein degradation [80]. Of note, no molecular alterations were observed in the proteasome or in the binding of the ligands to protein target or the E3 ligases.

Concluding remarks
Exploitation of the protein degradation machinery for therapeutic purposes opens new possibilities to target proteins involved in pathophysiological processes. Although important advances have been made using PROTAC technology, there are still many challenges for their clinical development. A crucial aspect is the selection of proteins which play a major oncogenic role in a certain tumor type, as is the case of the AR in prostate cancer or the ER in breast cancer. Optimization of the ligases used in the design of PROTACs for specific tumor tissues or cell types, or vectorization of the compounds with specific antibodies are strategies to be implemented and exploited. In addition, selection of the best combination with other therapies could reduce side effects augmented activity. PROTACs are not limited to cancer therapy and they are under investigation in all diseases where an accumulation of proteins are important in
their pathogenesis. That is the case in some neurodegenerative diseases or in conditions where degradation of a protein could have major impact than its enzymatic inhibition, as in the case of IRAK4 targeting in autoimmune diseases [81, 82]. Finally in situations where the target has a scaffolding role that cannot be inhibited by a conventional inhibitor or forms part of a hard-to-drug target, PROTACs could play a central role [82]. In conclusion, the first steps have been taken and offer hope for the incorporation of this family of agents in the clinic.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13046-020-01672-1.

Additional file 1: Supplementary Table 2. Reported studies describing PROTACs [45–49, 52–53, 56, 60, 66, 75, 77, 83–91].

Abbreviations
AR: Androgen receptor is a nuclear receptor activated by androgenic hormones, including testosterone and dihydrotestosterone; BET: Bromo and Extraterminal Domain is a protein domain that recognizes acetylated lysine residues. Members of this family include BRD2, BRD3, BRD4 and BRDT; BTK: Brutons tyrosine kinase is a tyrosine kinase encoded by the BTK gene in humans. Mutations in this kinase are associated with haematologic malignancies; CRBN: Cereblon is a protein that in humans is encoded by the CRBN gene. Cereblon forms an E3 ubiquitin ligase complex that is involved in the ubiquitination of several proteins. It is the target of immunomodulatory IMiDs; IAP1: Inhibitor of apoptosis protein 1(also named BIRC2), codes for the cellular inhibitor of apoptosis protein-1 that is involved in the ubiquitination of the pro-survival kinase TAK1; DUBs: Deubiquitinating enzymes are a group of proteases that cleave ubiquitin from proteins, therefore avoid the degradation of proteins via the proteasome; IMiD: Immunomodulatory drugs include thalidomide, lenalidomide or pomalidomide; PROTACs: They consist of two linked molecules: one capable of engaging an E3 ubiquitin ligase, and another that binds to a target protein that is of interest for proteasomal degradation; TFs: A class of proteins that control, by binding to a certain DNA sequence, the transcription of genetic information from DNA to messenger RNA.

Acknowledgements
Instituto de Salud Carlos III (FIS PI19/00808), ACEPAIN, ALMOM, ACMUMA, UCCTA, Diputación Albacete, ISCIII, CRIS Cancer Foundation, the Ministry of Economy and Competitiveness of Spain (BFU2015-71371-R), and the European Community through the Regional Development Funding Program (FEDER).

Authors’ contributions
All authors have approved and contributed equally.

Funding
This work has been supported by Instituto de Salud Carlos III (PI19/00808), ACEPAIN; Diputación de Albacete, CIBERONC, and CRIS Cancer Foundation (to A. Ocaña). Ministry of Economy and Competitiveness of Spain (BFU2015–71371-R), the Instituto de Salud Carlos III through the Spanish Cancer Centers Network Program (RD12/0036/0003) and CIBERONC, the scientific foundation of the AECC and the CRIS Foundation (to A. Pandiella). The work carried out in our laboratories receive support from the European Community through the regional development funding program (FEDER).

Availability of data and materials
Data are available upon reasonable request to the corresponding author.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not Applicable.

Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author details
1Experimental Therapeutics Unit, Medical Oncology Department, Hospital Clínico San Carlos, and IDIISC, Madrid, Spain. 2Centro de Investigación Biomédica en Red Oncología (CIBERONC), Madrid, Spain. 3Centro Regional de Investigaciones Biomédicas, Castilla-La Mancha University (UCLM), Albacete, Spain. 4UMCC-CSIC and IBSAL, Salamanca, Spain.

Received: 9 July 2020 Accepted: 10 August 2020
Published online: 15 September 2020

References
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. 2. Ocaña A, et al. Refining early Antitumoral drug development. Trends Pharmacol Sci. 2018;39:922–5. 3. Scapria M, et al. Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov. 2019;18:949–63. 4. Inobe T, Matuschek A. Paradigms of protein degradation by the proteasome. Curr Opin Struct Biol. 2014;24:156–64. 5. An S, Fu L. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018;36:553–62. 6. Bushweller JH. Targeting transcription factors in cancer - from undruggable to reality. Nat Rev Cancer. 2019;19:611–24. 7. Chen A, Koheler A. Transcription Factor Inhibition: Lessons Learned and Emerging Targets. 2020. https://doi.org/10.1016/j.molmed.2020.01.004. 8. Yu J-M, et al. TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription. Nat Commun. 2019:105720. 9. Mullard A. Arvinas’ PROTACs pass first safety and PK analysis. Nat Rev Drug Discov. 2019;18:895. 10. Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366:818–22. 11. Bard JAM, et al. The 26 S proteasome utilizes a kinetochary gradient to prioritize substrate degradation. J Cell. 2019;177:286–98 e15. 12. Ballabio A, Bonifacino JS. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat Rev. Mol. Cell Biol. 2020;21:101–18. 13. Dvela-Levitt M, et al. Small molecule targets TMED9 and promotes Lysosomal degradation to reverse Proteinopathy. Cell. 2019;178:521–35 e23. 14. Bard JAM, et al. Structure and function of the 26 S proteasome. Annu Rev Biochem. 2018;87:697–724. 15. Ravid T, Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat. Rev. Mol. Cell Biol. 2008;9:656–90. 16. Thrower JS, et al. Recognition of the polyubiquitin proteolytic signal. EMBO J. 2000;19:994–102. 17. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503–33. 18. Schultman BA, Harper JW. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol. 2009;10:319–31. 19. Poow J, et al. Highly selective PTK2 proteolysis targeting chimeras to probe focal adhesion kinase scaffolding functions. J Med Chem. 2019;62:2508–20. 20. van Wijk SJL, Timmers HTM. The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB J Off Publ Fed Am Soc Exp Biol. 2010;24:981–93. 21. Metzger MB, et al. HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci. 2012;125:531–7. 22. Sklar JP, Pagano M. Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr Opin Cell Biol. 2002;14:186–24. 23. Zheng N, Shabek N. Ubiquitin ligases: structure, function, and regulation. Annu Rev Biochem. 2017;86:129–57. 24. Sakamoto KM, et al. Proteasome chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A. 2001;98:8554–9.
25. Schneekloth AR, et al. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg Med Chem Lett. 2008;18:9004–8.

26. Van Molle L, et al. Dissecting fragment-based lead discovery at the von Hippel-Lindau protein/hypoxia inducible factor 1alpha protein-protein interface. Chem Biol. 2012;19:1300–12.

27. Galdeano C, et al. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J Med Chem. 2014;57:8657–63.

28. Soares P, et al. Group-based optimization of potent and cell-active inhibitors of the von Hippel-Lindau (VHL) E3 ubiquitin ligase: structure-activity relationships leading to the chemical probe (Z)-4R-(1-(31)-Cyanocloprop-1-en-2-yl)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methyloxazol-5-yl)benzyl)pyrrolidine-2-carboxamido (VH298). J Med Chem. 2018;61:599–618.

29. Bargagna-Mohan P, et al. Use of PROTACs as molecular probes of angiogenesis. Bio Med Chem Lett. 2005;15:2724–7.

30. Sakanoto KM, et al. Development of PROTacs to target cancer-promoting proteins for ubiquitination and degradation. Mol Cell Proteomics. 2003;2:1350–8.

31. Winter GE, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348:1376–81.

32. Bondeson DP, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11:611–7.

33. Zengerle M, et al. Selective small molecule induced degradation of the BET Bromodomain protein BRD4. ACS Chem Biol. 2015;10:1770–7.

34. Lu J, et al. Hijacking the E3 ubiquitin ligase Cereblon to efficiently target BET and BRD7. J Med Chem. 2019;62:699–711.

35. Filippakopoulos P, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067–72.

36. Shi C, et al. PROTAC-induced BET protein degradation exhibits potent anti-angiogenesis efficacy at low anti-angiogenic dose. Cell Death Dis. 2019;10:812.5

37. Qin C, et al. Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the Bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression. J Med Chem. 2018;61:6685–704.

38. Noble-Jaime-MDM, et al. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. J Exp Clin Cancer Res. 2019;38:383.

39. Bai L, et al. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 2017;77:2476–87.

40. Raina K, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. PLoS Natl Acad Sci U S A. 2016;11:724–9.

41. Remillard D, et al. Degradation of the BAF complex factor BRD9 by Heterobifunctional ligands. Angew Chem Int Ed Engl. 2015;54:6573–83.

42. Zoppo V, et al. Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel-Lindau (VHL) based dual degrader probe of BRD9 and BRD7. J Med Chem. 2019;62:5699–726.

43. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13:337–56.

44. Ocana A, et al. BET inhibitors as novel therapeutic agents in breast cancer. Nature. 2010;468:1067–72.

45. Bian J, et al. Discovery of Wogonin-based PROTACs against CDK9 and selective von Hippel-Lindau (VHL) based dual degrader probe of BRD9 and BRD7. J Med Chem. 2019;62:5699–726.

46. McColl W, et al. Development of a novel B-cell lymphoma 6 (BCL6) PROTAC to provide insight into small molecule targeting of BCL6. ACS Chem Biol. 2018;13:3131–41.

47. Khan S, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938–47.

48. Su S, et al. Potent and preferential degradation of CDK9 via proteolysis targeting chimera degraders. J Med Chem. 2019;62:7575–82.

49. Brand M, et al. Homolog-selective degradation as a strategy to probe the function of CDK6 in AML. Cell Chem Biol. 2019;26:300–6.

50. Liu L, et al. UbHub: a data hub for the explorers of ubiquitination pathways. Bioinforma Oxf Engl. 2019;35:S282–4.

51. Zhang X, et al. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. Nat Chem Biol. 2019;15:737–46.

52. Hughes SJ, Culli A. Molecular recognition of ternary complexes; a new dimension in the structure-guided design of chemical degraders. Essays Biochem. 2017;61:505–16.

53. Roy RD, et al. Cooperative binding mitigates the high-dose hook effect. BMC Syst Biol. 2017;11:74.

54. Burslem GM, et al. The advantages of targeted protein degradation over inhibition. An RTK case study. Cell Chem Biol. 2018;25:67–77 e3.

55. Olson CM, et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol. 2018;14:163–70.

56. Testa A, et al. 3-Fluoro-4-hydroxyprolines: synthesis, conformational analysis, and Stereoselective recognition by the VHL E3 ubiquitin ligase for targeted protein degradation. J Am Chem Soc. 2018;140:9299–313.

57. Chen K-H, et al. Impact of target warhead and linkage vector on inducing protein degradation: comparison of Bromodomain and extra-terminal (BET) degraders derived from Triazololazine (JQ1) and Tetrahydroquinoxaline (i-BET726) BET inhibitor scaffolds. J Med Chem. 2018;61:504–13.

58. Smith BE, et al. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat Commun. 2019;10:1311.

59. Cromm PM, et al. Addressing kinase-independent functions of Fak via PROTAC-mediated degradation. J Am Chem Soc. 2018;140:17019–26.

60. Bondeson DP, et al. Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell Chem Biol. 2018;25:78–87 e5.

61. Zeng M, et al. Exploring targeted degradation strategy for oncogenic KRAS(G12C). Cell Chem Biol. 2020;27:19–31 e6.

62. Khongorzul P, et al. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18:13–9.

63. Niza E, et al. Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of Dasatinib in HER2+ Metastatic breast cancer. Nanomater. Basel Switz. 2019;9.

64. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315–37.

65. Pillow TH, et al. Antibody conjugation of a chimeric BET degrader enables in vivo activity. ChemMedChem. 2020;15:17–25.

66. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PO-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107:13075–80.

67. Woyach JA, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibritinib. N Engl J Med. 2014;370:2286–94.

68. Pagliarini R, et al. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep. 2015;16:280–96.

69. Timworth CP, et al. PROTAC-mediated degradation of Bruton’s tyrosine kinase is inhibited by covalent binding. ACS Chem Biol. 2019;14:342–7.

70. Flanagan JJ, Qian Y, Gough SM. ARV-471, an estrogen receptor PROTAC™ protein degrader for breast cancer. SABCS. 2018;P5–04–18.

71. Salami J, et al. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2018;1:100.

72. Zhang L, et al. Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in Core components of E3 ligase complexes. Mol Cancer Ther. 2019;18:302–11.

73. Ottis P, et al. Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway. ACS Chem Biol. 2019;14:2215–23.

74. Mayor-Ruiz C, et al. Plasticity of the Cullin-RING ligase repertoire shapes sensitivity to ligand-induced protein degradation. Mol. Cell. 2019;75:849–58 e8.

75. Silva MC, et al. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. Elife. 2019;8:e45457.
82. Nunes J, et al. Targeting IRAK4 for degradation with PROTACs. ACS Med Chem Lett. 2019;10:1081–5.
83. Saenz DT, et al. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017;31:1951–61.
84. Tovell H, et al. Design and characterization of SGK3-PROTAC1, an isoform specific SGK3 kinase PROTAC degrader. ACS Chem Biol. 2019;14:2024–34.
85. Bai L, et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell. 2019;36:498–511 e17.
86. Vollmer S, et al. Design, synthesis, and biological evaluation of MEK PROTACs. J Med Chem. 2020;63:157–62.
87. Burslem GM, et al. Enhancing Antiproliferative activity and selectivity of a FLT-3 inhibitor by proteolysis targeting chimera conversion. J Am Chem Soc. 2018;140:16428–32.
88. Tovell H, et al. Rapid and reversible knockdown of endogenously tagged Endosomal proteins via an optimized HaloPROTAC degrader. ACS Chem Biol. 2019;14:882–92.
89. Lai AC, et al. Modular PROTAC Design for the Degradation of oncogenic BCR-ABL. Angew. Chem. Int. Ed Engl. 2016;55:807–10.
90. Chen H, et al. Pomalidomide hybrids act as proteolysis targeting chimeras: synthesis, anticancer activity and B-Raf degradation. Bioorg Chem. 2019;87:191–9.
91. Li Y, et al. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J Med Chem. 2019;62:448–66.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.